The simultaneous $4M buys by a director and a major institutional holder suggest strong conviction in near-term prospects. Monitor upcoming earnings or pipeline updates as potential catalysts. The stock has room to re-rate if fundamentals follow through.
Price Chart
Executive Summary
Alamar Biosciences insiders and a major shareholder jointly purchased $8 million in stock, with Director Naclerio and 10% owner Illumina Innovation Fund II each buying $4 million at $17 per share. This coordinated open-market buying signals strong confidence amid a wave of non-cash derivative transactions by executives.
Key Financial Metrics
Key Facts
- Director Naclerio purchased 235,294 shares at $17 for $4.0M in open-market buying.
- Illumina Innovation Fund II, a 10% owner, matched the $4.0M purchase.
- Total cluster value is $8.0M, representing 0.53% of the $1.5B market cap.
- Multiple executives (CEO, CFO) conducted large non-cash derivative conversions and awards totaling tens of millions of shares, but these had $0 economic value.
- All open-market transactions were buys; no sales occurred in the 7-day window.
Financial Impact
$8.0 million in combined open-market purchases at $17 per share
Risk Factors
- Open-market purchases are positive but do not guarantee future performance.
- Non-cash derivative transactions dominate the filing volume and could lead to future dilution if converted to common shares.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-ALMR-1776889029576 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 14, 2026 11d ago | 144 | $27.42 | awaiting T+60 | — | $30.71 (−12.00%) |
Oct 14, 2026 11d ago | 144 | $27.42 | awaiting T+60 | — | $30.71 (−12.00%) |
Oct 14, 2026 11d ago | 144 | $27.42 | awaiting T+60 | — | $30.71 (+12.00%) |
Oct 5, 2026 20d ago | Press Release | $32.26 | awaiting T+60 | — | $30.71 (−4.80%) |
Sep 24, 2026 4w ago | Press Release | $32.80 | awaiting T+60 | — | $30.71 (−6.37%) |
Sep 1, 2026 7w ago | 8-K | $30.49 | awaiting T+60 | — | $30.71 (+0.72%) |
Aug 10, 2026 10w ago | 8-K | $36.57 | awaiting T+60 | — | $30.71 (−16.02%) |
Jul 13, 2026 15w ago | Press Release | $27.40 $32.26 | ▲ +17.74% | ▲ +13.74% | $30.71 (+12.08%) |
Jul 10, 2026 15w ago | Press Release | $28.42 $38.13 | ▲ +34.17% | ▲ +31.53% | $30.71 (+8.06%) |
May 8, 2026 24w ago | 8-K | $23.96 $27.11 | ▲ +13.15% | ▲ +8.31% | $30.71 (+28.17%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers